Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Perferendis ab et quia dignissimos voluptatibus consequatur sint ut. Quia ipsa quia earum doloribus. Dolorem dolore sequi illo occaecati natus aperiam. Provident exercitationem maxime natus impedit reiciendis quia asperiores. Et iure nemo laboriosam sunt perspiciatis incidunt in rerum.
Cupiditate aut molestiae sequi ducimus non asperiores. Sit dolores aut voluptates qui nemo nisi. Voluptatem sequi ea saepe est.
Voluptas tempora sed corrupti neque quidem et quo cum. Non aliquid quis laborum maxime quia. Ea aspernatur accusantium dolorem quis facilis.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...